AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20112576
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of the same color for oral use and external application, with the same delivery times and therapy duration as the treatment group.
Trial: 7986160
Drug: Propranolol hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol hydrochloride (nonselective beta 1‐ and beta 2‐blocker)
Trial: 7986160
Drug: Metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol tartrate (selective beta 1‐blocker)
Trial: 2623708
Drug: Preventive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive care program in dental practice, details on dosage and duration not specified.
Trial: 1184719
Drug: Clonidine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.15 mg iv)
Trial: 1184719
Drug: Apomorphine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (selective dopamine receptor agonist)
Trial: 24221463
Drug: 33‐gauge injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33‐gauge injection device without a speculum
Trial: 21485071
Drug: Chinese drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drugs for supplementing qi-blood and nourishing Gan-Shen (Cuhuangti Granule and Jinghou Zengzhi Granule)
Trial: 12742279
Drug: Ximelagatran 20
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 20 mg twice daily
Trial: 12742279
Drug: Ximelagatran 40
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 40 mg twice daily
Trial: 12742279
Drug: Ximelagatran 60
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 60 mg twice daily
Trial: 26699670
Drug: PEAS-Diet (interview-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEAS-Diet (interview-administered version)
Trial: 24885132
Drug: Surgical antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical antimicrobial prophylaxis administered in the anesthesia room (75 to 30 minutes before incision)
Trial: 24885132
Drug: Surgical antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical antimicrobial prophylaxis administered in the operating room (less than 30 minutes before incision)
Trial: 22457015
Drug: Clevidipine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevidipine (2.0 mg/h, titrated to target dose up to 16.0 mg/h)
Trial: 17431817
Drug: Phenylalanine-free amino
RxNorm normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylalanine-free amino acid supplements without LCPUFA
Trial: 7625106
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA yeast-derived HB vaccine booster dose
Trial: 7625106
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of primary immunization
Trial: 7625106
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of primary immunization
Trial: 7625106
Drug: Age-related antibody
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-related antibody levels
Trial: 357071
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg 3 times a day
Trial: 357071
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg 3 times a day
Trial: 357071
Drug: Metoclopramide 30
RxNorm normalized name: metoclopramide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 30 mg daily
Trial: 29533252
Drug: Aquatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic therapy
Trial: 20931060
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salts (ORS)
Trial: 31264950
Drug: Intravenous contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous contrast agent administration (CT angiography)
Trial: 31264950
Drug: Intra-arterial contrast
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial contrast agent administration (catheterization)
Trial: 23831913
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Q10 daily for 12 weeks
Trial: 21246788
Drug: Propiverin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverin 30 mg daily
Trial: 21246788
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propiverin 30 mg daily and tamsulosin 0.4 mg daily
Trial: 17576207
Drug: Oral delayed
RxNorm normalized name: Urimax, oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delayed release granules
Trial: 17576207
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL rectal foam
Trial: 17576207
Drug: Rectal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal delivery of 5‐ASA
Trial: 9869017
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine 10-40 mg daily, captopril 12.5-50.0 mg daily, hydrochlorothiazide 12.5-50.0 mg daily)
Trial: 8005305
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist therapy for 12 weeks
Trial: 22451196
Drug: Aripiprazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (10 mg)
Trial: 28334771
Drug: Degarelix 360
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix 360 mg every 84 days
Trial: 28334771
Drug: Degarelix 480
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix 480 mg every 84 days
Trial: 25287168
Drug: 280 mg
RxNorm normalized name: levodopa 280 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 mg of acid‐resistant lipase
Trial: 18535812
Drug: SCIT (Subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCIT (Subcutaneous Immunotherapy)
Trial: 18535812
Drug: SLIT (Sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLIT (Sublingual Immunotherapy)
Trial: 6139628
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D or alfacalcidol treatment; specific dosage and duration not mentioned.
Trial: 22476240
Drug: Pregabalin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (100 mg preoperatively, then 50 mg every 12 hrs)
Trial: 19608565
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa) for final oocyte maturation
Trial: 17890944
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy without thalidomide
Trial: 17890944
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with thalidomide
Trial: 27525826
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment for 4 weeks, using two acupoints: Baihui and Shenting
Trial: 27525826
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified what treatment they received)
Trial: 15939567
Drug: Delayed-treatment control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment control condition
Trial: 18462423
Drug: IPL plus
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL plus BTX (8 U total dose, 0.1 mL intradermal injections in one cheek)
Trial: 16378562
Drug: No modifications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No modifications to drug treatment
Trial: 16378562
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of antihypertensive drugs taken
Trial: 16378562
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of antihypertensive drug modifications
Trial: 8629830
Drug: Adjuvant therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapies (not specified)
Trial: 1670907
Drug: Upright tilt-table
RxNorm normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upright tilt-table test with isoproterenol infusion (1 to 3 micrograms/minute)
Trial: 1670907
Drug: Therapy with
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with beta-blockers, disopyramide, transdermal scopolamine, or hydroflurocortisone
Trial: 31132897
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% desoximetasone spray with twice daily phone call reminders
Trial: 26956140
Drug: Single SPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SPI visit with a diabetes treatment video
Trial: 16259540
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 or 20 mg/day)
Trial: 15493437
Drug: Visual attention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Visual attention therapy (12 one-hour sessions, computer-based)
Trial: 11101481
Drug: Phylloquinone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone (1000 microg daily for 2 weeks)
Trial: 8956929
Drug: Tiagabine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (30 mg/day)
Trial: 8956929
Drug: Tiagabine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (mean 65.7 mg/day, range 30-80 mg/day)
Trial: 8956929
Drug: Tiagabine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (mean 67.6 mg/day, range 24-80 mg/day)
Trial: 1488558
Drug: RU 41740
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 41740 long-term treatment for 6 months
Trial: 1488558
Drug: RU 41740
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 41740 standard treatment for 3 months
Trial: 31437659
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge before training sessions
Trial: 31437659
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge before training sessions
Trial: 24650860
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention (n=552)
Trial: 19793169
Drug: 1 liter
RxNorm normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL GEL [Hand Sanitizer Cristal Prime 1 liter]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 liter PEG with 200 mg dimethylpolysiloxane 3 hours before CE
Trial: 15715188
Drug: Oral clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clarithromycin (Klaricid XL) once-daily for 3 months
Trial: 10090328
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (15 p.p.m.)
Trial: 10090328
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without inhaled nitric oxide)
Trial: 7751833
Drug: Buspirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (10 or 15 mg)
Trial: 7751833
Drug: Low-dose training
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose training phase
Trial: 7751833
Drug: Self-reported effects
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported effects of both drugs
Trial: 399857
Drug: Increasing weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Increasing weekly injections of house dust mite extract for 18 weeks followed by monthly injections to complete 18 months of treatment
Trial: 399857
Drug: Similar injections
RxNorm normalized name: Antigonadotropins and similar agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar injections for 18 weeks followed by placebo injections up to 18 months
Trial: 399857
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 18 months
Trial: 30871894
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no physiotherapy treatment)
Trial: 27865639
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Nitinol stent (NS) with cryoplasty (CR) and drug-coated balloon
Trial: 23504694
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg once daily) and asunaprevir (600 mg twice daily) for 24 weeks (Group A)
Trial: 23504694
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg once daily) and asunaprevir (600 mg twice daily) with peginterferon alfa-2a and ribavirin for 24 weeks (Group B)
Trial: 19622986
Drug: Birth weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth weight below 4,000 g
Trial: 12508046
Drug: Mandibular two-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular two-implant retained overdentures (IOD)
Trial: 8857075
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of budesonide (2 mg in 100 ml fluid)
Trial: 8857075
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of budesonide (2 mg in gelatine capsule)
Trial: 29879048
Drug: Control (false
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (false TAES followed by saline injection after 30 minutes)
Trial: 29879048
Drug: TAES (TAES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAES (TAES followed by saline injection after 30 minutes)
Trial: 29879048
Drug: Sufentanil (false
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (false TAES followed by low‐dose sufentanil (0.1 μg/kg) injection after 30 minutes)
Trial: 29879048
Drug: Sufentanil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plus TAES (TAES followed by low‐dose sufentanil injection after 30 minutes)
Trial: 19467896
Drug: PRP administered
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP administered to lower responders
Trial: 16336071
Drug: Comprehensive family‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive family‐based behavioral treatment program
Trial: 16336071
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment incorporating reinforcing children for engaging in alternative behaviors to eating
Trial: 12490092
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group received a primary dose of 1000 units of the new vaccine.
Trial: 12490092
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group received a primary dose of 500 units of the new vaccine.
Trial: 12490092
Drug: Havrix group
RxNorm normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Havrix group received a primary dose of 1440 enzyme-linked immunosorbent assay units of Havrix.
Trial: 12490092
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (1000 units) at month 6.
Trial: 12490092
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (1000 units) one month after booster dose.
Trial: 2205290
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms ethinyl oestradiol daily by mouth for 10 days
Trial: 2205290
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily by mouth for 10 days
Trial: 29712515
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 30 IU of oxytocin started before uterine incision (Group I)
Trial: 29712515
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 30 IU of oxytocin started after clamping the umbilical cord (Group II)
Trial: 23636616
Drug: Asthmatic children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthmatic children (AG) without supplements
Trial: 21510853
Drug: Background stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background stroke care (limited, no thrombolytic therapy)
Trial: 17360872
Drug: malaria vaccine
RxNorm normalized name: malaria vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: malaria vaccine regimen FP9 ME‐TRAP/MVA ME‐TRAP
Trial: 17360872
Drug: rabies vaccine
RxNorm normalized name: RABIES VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabies vaccine
Trial: 11157317
Drug: High isoflavone
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High isoflavone diet (132 +/- 22 mg isoflavones/d)
Trial: 11157317
Drug: Low isoflavone
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low isoflavone diet (65 +/- 11 mg isoflavones/d)
Trial: 11157317
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (7.1 +/- 1.1 mg isoflavones/d)
Trial: 7840430
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (daily alcohol intake < 40 g)
Trial: 2628537
Drug: Adrenaline 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 0.01 mg/kg
Trial: 2628537
Drug: Salbutamol 0.007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 0.007 mg/kg
Trial: 31823057
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of paracetamol, anti-neuropathic pain drugs, and opioids in the intervention group
Trial: 30205020
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in group O (osteoporosis)
Trial: 30205020
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in group C (control)
Trial: 25738212
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg/d) plus Vitamin D3 placebo
Trial: 21872439
Drug: Non-statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-statin treatment (Control)
Trial: 19570393
Drug: Insulin added
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin added into 'all in one' bags
Trial: 19570393
Drug: Insulin added
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin added into syringes and transfused by infusion pump
Trial: 15995106
Drug: Bacitracin solution
RxNorm normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bacitracin solution (group B)
Trial: 15995106
Drug: Castile soap
RxNorm normalized name: CASTILE SOAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Castile soap solution (group C)
Trial: 11604622
Drug: 5-fluorouracil solution
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil solution for 5 minutes after excision
Trial: 29578578
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg every 2 weeks
Trial: 23756581
Drug: Grana Padano
RxNorm normalized name: Padang cassia oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grana Padano cheese containing lysozyme (30 g)